Kangpu Biopharmaceuticals, Ltd.
Shanghai
About Kangpu Biopharmaceuticals, Ltd.
Kangpu is focused on developing small molecule drugs targeting immuno-modulating sites to develop treatments for cancer, autoimmune diseases and inflammation. The company has developed proprietary technologies to generate and degrade ubiquitin-protein. It also has a drug discovery combination platform called X-Synergy®.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $66.7M
- Funding stage: Early Stage Venture
- Last round: Series B (Aug 2023)
- Website: kangpugroup.com
- Phone: [email protected]
Industries & Categories
Biopharma, Clinical Trials, Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/kangpu-biopharmaceuticals-ltd-161510 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.